Subscribe
The latest psychology and neuroscience discoveries.
My Account
  • Mental Health
  • Social Psychology
  • Cognitive Science
  • Psychopharmacology
  • Neuroscience
  • About
No Result
View All Result
PsyPost
PsyPost
No Result
View All Result
Home Exclusive Psychopharmacology Ketamine

Ketamine can rapidly reduce symptoms of PTSD and depression, new study finds

by C. Michael White
January 22, 2024
in Ketamine
(Photo credit: OpenAI's DALL·E)

(Photo credit: OpenAI's DALL·E)

Share on TwitterShare on Facebook
Stay informed on the latest psychology and neuroscience research—follow PsyPost on LinkedIn for daily updates and insights.

The drug ketamine can reduce the symptoms of post-traumatic stress disorder, or PTSD, and symptoms of depression in patients as early as a day after injection. That is the key finding of my team’s new meta-analysis, just published in the journal Annals of Pharmacotherapy.

Ketamine is an anesthetic that is sometimes used as a substance of abuse but is increasingly being explored as a treatment for a range of mental health conditions.

We analyzed six randomized controlled trials representing 259 patients with moderate to severe PTSD. In all trials, about half were injected with ketamine. The rest received either salt water or the drug midazolam, a benzodiazepine like Xanax that is also used as an anesthetic agent.

Patients receiving ketamine saw their PTSD symptoms reduced by about 25% both at one day and one week after therapy. But if patients received repeated injections over four weeks, PTSD symptoms declined by only 12%. Reduction of depression symptoms were more modest but still significant.

In most of these trials, patients only received a single shot; in the other two, they were given an injection at the same dose six or more times over two to four weeks. The benefits after the first injection were similar across studies, but it’s unclear how well additional doses of ketamine over time maintain these benefits.

Overall, the benefits of even a single ketamine injection occur rapidly, but are modest in magnitude. The best regimen to maintain these benefits by reinjecting ketamine has not been determined.

Why it matters

PTSD, a debilitating mental health disorder, occurs when past trauma causes flashbacks, nightmares, depressed mood, anxiety and avoidance of activities that could trigger traumatic memories. Patients with PTSD are twice as likely to attempt suicide than the general population.

About 13 million Americans have PTSD in a given year, which translates to nearly 5% of the adult population. PTSD is caused by experiencing or witnessing a traumatic event. Many combat veterans have the disorder, as do survivors of physical assault, natural disasters, child abuse and sexual abuse. Those with moderate to severe disease cases lose an average of about three and a half days of work per month due to triggered symptoms or treatment for the illness.

Trauma-focused psychotherapy – techniques that help patients recall, process and respond to traumatic memories – is the treatment of choice for PTSD, but it can take several weeks to see benefits, and not all patients respond.

For these people, antidepressants such as paroxetine, sertraline and venlafaxine are recommended as alternatives, or as an addition to psychotherapy.

But like psychotherapy, these drugs may not work for a while – about five to eight weeks – unlike ketamine, which seems to begin working almost immediately. That said, the reduction in PTSD and depression symptoms over time following ketamine injection is about the same as what the traditional antidepressants provide once they take effect.

Because some people with severe PTSD may be experiencing suicidal thoughts, time is of the essence; they simply might not be able to wait for traditional options to begin working. Ketamine might be an effective bridge to immediately reduce patients’ symptoms until trauma-focused psychotherapy and other antidepressants can kick in.

What still isn’t known

The big unknown with using ketamine for PTSD and depressive symptoms is how often the injections are needed. The data simply is not robust enough to determine whether multiple doses maintain the effects better than simply using a single dose.

Ketamine costs around US$800 per injection, so knowing how much to administer each treatment and how many injections to give over time is important.

Importantly, ketamine can be abused. If purchased from unlicensed pharmacies or online stores, the ketamine product is not approved by the Food and Drug Administration. It may not have the correct dose, may have expired or might not even have any ketamine in it. Or, it may contain a substitute drug with a dangerous active ingredient, like the synthetic street drug LSD. Such fake products can harm or even kill patients.

 

This article is republished from The Conversation under a Creative Commons license. Read the original article.

The Conversation

TweetSendScanShareSendPin2ShareShareShareShareShare

RELATED

Neuroscience research sheds light on ketamine’s strange effect on our sense of touch
Ketamine

Ketamine’s antidepressant effects appear unrelated to stress hormones, study finds

May 15, 2025

New research suggests that hormones linked to the body’s stress response do not influence how people with treatment-resistant depression respond to ketamine. However, lower hormone levels were associated with longer depressive episodes, pointing to possible biomarkers for depression duration.

Read moreDetails
Unexpected results from a ketamine study might reshape depression research
Depression

Unexpected results from a ketamine study might reshape depression research

May 3, 2025

A new study suggests chronic opioid use may interfere with the brain’s natural ability to respond to placebo antidepressants. Surprisingly, ketamine’s antidepressant effects remained intact—raising intriguing questions about how drugs, expectations, and mood-regulating systems interact.

Read moreDetails
Ketamine shows promise for treatment-resistant PTSD in psychedelic-style therapy settings
Ketamine

Ketamine shows promise for treatment-resistant PTSD in psychedelic-style therapy settings

March 19, 2025

Ketamine therapy, when combined with psychedelic-inspired support, shows strong potential for reducing PTSD symptoms in those who haven’t responded to conventional treatments, new research suggests.

Read moreDetails
Ketamine-assisted psychotherapy helps rage-filled man overcome antisocial traits and severe alcoholism
Ketamine

Ketamine-assisted psychotherapy helps rage-filled man overcome antisocial traits and severe alcoholism

February 16, 2025

A 44-year-old man with alcoholism, depression, and antisocial personality traits underwent three years of ketamine-assisted psychotherapy, resulting in reduced alcohol use, depression, and violent thoughts.

Read moreDetails
Ketamine shows promise for severe obsessive-compulsive disorder in new study
Ketamine

Ketamine shows promise for severe obsessive-compulsive disorder in new study

February 12, 2025

A small, preliminary study suggests that a single intramuscular ketamine injection may rapidly ease symptoms in patients with treatment-resistant obsessive-compulsive disorder.

Read moreDetails
New neuroscience research reveals the remarkable impact of exercise on brain cells
Ketamine

Breakthrough study shows how ketamine may ease dyskinesia in Parkinson’s patients

January 23, 2025

A study found that levodopa-induced dyskinesia disconnects the motor cortex from movement control, allowing abnormal movements. Ketamine reduced these movements, restored some brain control, and altered neural interactions, showing promise as a potential treatment.

Read moreDetails
Experiences of awe may drive ketamine’s antidepressant benefits
Ketamine

Experiences of awe may drive ketamine’s antidepressant benefits

January 12, 2025

Ketamine infusion induces feelings of awe, which may mediate its antidepressant effects. Stronger awe experiences were linked to greater, longer-lasting depression symptom improvements, independent of dissociative symptoms

Read moreDetails
Muscle contractions release chemical signals that promote brain network development
Ketamine

Ketamine’s rapid antidepressant effects traced to overlooked brain cells

December 23, 2024

Researchers found that ketamine reduces "giving up" behavior in zebrafish by altering astrocyte activity, suggesting its antidepressant effects involve non-neuronal brain cells and promoting resilience against futility-induced passivity.

Read moreDetails

SUBSCRIBE

Go Ad-Free! Click here to subscribe to PsyPost and support independent science journalism!

STAY CONNECTED

LATEST

Hispanic adolescents experience later sleep timing and greater social jet lag than peers, study finds

Student loan debt doesn’t deter civic engagement — it may actually drive it, new research suggests

Understanding “neuronal ensembles” could revolutionize addiction treatment

Not bothered by celebrity infidelity? This psychological trait might be why

Genetic factors may influence how well exercise buffers against childhood trauma

Tips for parents in talking with your kids about your partner’s mental illness

Subjective cognitive struggles strongly linked to social recovery in depression

New research suggests the conservative mental health advantage is a myth

         
       
  • Contact us
  • Privacy policy
  • Terms and Conditions
[Do not sell my information]

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

Subscribe
  • My Account
  • Cognitive Science Research
  • Mental Health Research
  • Social Psychology Research
  • Drug Research
  • Relationship Research
  • About PsyPost
  • Contact
  • Privacy Policy